June 18, 2009 (FinancialWire) — Biopharmaceutical firm ImmunoGen, Inc. (NASDAQ: IMGN) said it has priced a public offering of five million shares of its common stock at $7 per share. The company said it expects to see net proceeds of around $33 million.

Oppenheimer & Co. (NYSE: OPY) is acting as the sole book-runner. ImmunoGen has granted the underwriters a thirty day option to purchase up to an additional 750,000 shares to cover over-allotments.

The offering is scheduled to close on or about June 23.

Waltham, Massachusetts-based ImmunoGen develops targeted anticancer therapeutics. The company’s collaborative partners include Genentech, sanofi-aventis, Biogen Idec, Biotest, Roche, Bayer HealthCare and Amgen.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.